Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French Trial Tragedy: FDA Launches 'FAAH' Safety Probe

This article was originally published in Scrip

Executive Summary

US regulators on Jan. 22 said they are conducting a safety probe of fatty acid amide hydrolase (FAAH) inhibitors being developed and studied in the US after one healthy volunteer in a French Phase I trial testing a product in that class died and five other participants experienced severe adverse neurological events.

Advertisement

Related Content

FAAH Inhibitor Trials Could Resume In US Following French Study Disaster Review

Topics

Advertisement
UsernamePublicRestriction

Register

SC064286

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel